Slide 1: Accelerating precision medicine
Accelerating precision medicine Evotec SE, H1 2022 Interim Report, 11 August 2022
Slide 2: Cautionary statement regarding forward-looking statements
Cautionary statement regarding forward-looking statements Information set forth in this presentation contains forward-looking statements, which involve a number of risks and uncertainties. All statements other than statements of historical fact are forward-looking statements, which are often indicat
Slide 3: Welcome: The Management Team
Welcome The Management Team Werner Enno Craig Matthias Cord Lanthaler Spillner Johnstone Evers Dohrmann CEO* CFO* COO* CBO CSO* PAGE 2 * Presenting in the call today
Slide 4: Agenda
Agenda Highlights Financial performance H1 2022 Scientific and operational performance H1 2022 ESG, Outlook and Guidance 2022 PAGE 3
Slide 5: Significant new partnerships based on data-driven platforms
Significant new partnerships based on data-driven platforms H1 2022 – Highlights & lowlights Highlights Major expansion and extension of targeted protein degradation alliance with BMS Several new integrated drug discovery, INDiGO, CMC, sample management agreements New collaborations with Almir
Slide 6: Keeping the pace
Keeping the pace Financials H1 2022 & FY 2022 guidance Undisrupted demand from all industry sectors Guidance refined Group revenues up 24% Very good top-line growth expected (€ 336.9 m vs. H1 2021: € 271.3 m) Total Group revenues € 715-735 m Like-for-like growth of Group revenues (April 2022
Slide 7: Agenda
Agenda Highlights Financial performance H1 2022 Scientific and operational performance H1 2022 ESG, Outlook and Guidance 2022 PAGE 6
Slide 8: Strong growth & investments into capacity, R&D, SG&A and M&A
Strong growth & investments into capacity, R&D, SG&A and M&A Condensed income statement H1 2022 – Evotec SE and subsidiaries in € m1) H1 2022 H1 2021 Change Revenue growth 24% Revenues 336.9 271.3 24% (19%, adjusted for fx-effects) Increasing share of unpartnered Gross margin 18.8% 20.8% – R&D (
Slide 9: High value alliances yield strong gross margin; Just – Evotec Biologics in build-up phase
High value alliances yield strong gross margin; Just – Evotec Biologics in build-up phase Revenues & Gross margin overview – Evotec SE and subsidiaries Revenues from contracts Gross margin Group base revenues up 26%, with customers (in € m) (in %) € 68.8 m to € 330.1 m. Base revenues Total Margin
Slide 10: Strong performance across all business lines
Strong performance across all business lines Segment information H1 2022 – Evotec SE and subsidiaries in € m1) Inter- EVT EVT segment Evotec Very strong growth versus H1 2021 Execute Innovate elimination Group EVT Execute: 26% growth including inter- Revenues 351.0 78.0 (92.1) 336.9 segment reve
Slide 11: Sequential growth acceleration yields margin improvement
Sequential growth acceleration yields margin improvement Condensed income statement Q2 2022 – Evotec SE and subsidiaries in € m1) Q2 2022 Q2 2021 Base revenues accelerated in Q2 Revenues 172.2 138.2 versus Q1 2022 across all business lines suggesting robust demand and Gross margin 17.9% 18.5% limi
Slide 12: Strong balance sheet supports accelerated growth
Strong balance sheet supports accelerated growth Balance sheet and liquidity – 31 Dec. 2021 vs. 30 June 20221) – Evotec SE and subsidiaries Balance sheet total Equity Ratio Total assets increased by ~3% in € m in % With upfront payment received from BMS, net debt leverage ratio further 2,235.2 2
Slide 13: Agenda
Agenda Highlights Financial performance H1 2022 Scientific and operational performance H1 2022 ESG, Outlook and Guidance 2022 PAGE 12
Slide 14: Platforms and technologies for more precision and efficiency
Platforms and technologies for more precision and efficiency Evotec today – 16 Sites and more than 4,400 employees USA Austria Italy Germany UK France >500 ~40 >850 >1,050 >950 >950 Branford Orth an der Donau Verona (Campus Hamburg (HQ) Abingdon Lyon Princeton Levi-Montalcini) & Goetti
Slide 15: Developing precise medicines with panomics & tech convergence
Developing precise medicines with panomics & tech convergence Overview R&D efficiency Precision medi- Right modality Just – Evotec platforms cine platforms drug design Biologics Data-driven R&D Autobahn to Cures – combining all relevant parts for an integrated, end-to-end approach PAGE 14
Slide 16: New and extended alliances underline growth strategy
New and extended alliances underline growth strategy Highlights in H1 2022 R&D efficiency Precision medi- Right modality Just – Evotec platforms cine platforms drug design Biologics Data-driven Autobahn Data-driven R&D Autobahn toto Cure Cures Several new and extended integrated drug discovery agr
Slide 17: Continued strong partnerships with precision medicine platforms
Continued strong partnerships with precision medicine platforms Overview in H1 2022 R&D efficiency Precision medi- Right modality Just – Evotec platforms cine platforms drug design Biologics Data-driven Autobahn Data-driven R&D Autobahn toto Cure Cures Ophtalmology; iPSC- and EVOpanOmics; Undisclose
Slide 18: Delivering health by expanding & improving cell therapy research
Delivering health by expanding & improving cell therapy research Overview H1 2022 R&D efficiency Precision medi- Right modality Just – Evotec platforms cine platforms drug design Biologics Data-driven Autobahn Data-driven R&D Autobahn toto Cure Cures QRBeta 1.0 – First generation cell therapy for
Slide 19: Evotec Cell Accelerator takes cell therapy to the next level
Evotec Cell Accelerator takes cell therapy to the next level EVOcells – World-class end-to-end infrastructure iPSC-derived QC & upscaling Pre-clinical Clinical manufacturing Market supply iPSC Platform cell types Oncology development Gene editing expertise & CMC Clinical Phase I / II / III1) Marketi
Slide 20: Building a iPSC-based cell therapy pipeline
Building a iPSC-based cell therapy pipeline Internal off-the-shelf cell therapy programmes Pre-clinical Pre-clinical Field Program / Project Disease area Exploratory research development IND / Phase 1 iPSC-based cell types iNK IO1) iNK Natural killer cells iM IO Anti-tumour iT αβ and γδ T cells cell
Slide 21: Shaping the value proposition to meet future demand
Shaping the value proposition to meet future demand Just – Evotec Biologics development update R&D efficiency Precision medi- Right modality Just – Evotec platforms cine platforms drug design Biologics Data-driven Autobahn Data-driven R&D Autobahn toto Cure Cures J.POD® Toulouse (France) EU: constru
Slide 22: Continuous process outperforming fed batch 20x
Continuous process outperforming fed batch 20x Large scale production readiness is imminent Fully end-to-end continuous process for late-stage products (> 25-day production) Kg DS1) per Bioreactor 40 1,000L 35 30 25 20 15 500L 10 5 0 Fed batch Hybrid 15d E2E >25d PAGE 21 1) DS = Drug Substance
Slide 23: Programmes of partners with increasing breadth and depth
Programmes of partners with increasing breadth and depth Just – Evotec Biologics client programmes No. of J.MD Pre-clinical Clinical Commercial Disease area programmes Discovery Optimization development manufacturing Manufacturing Broad basis for sustained growth 1 > 15 partners / 18 programmes On
Slide 24: Strong growth of biologics business
Strong growth of biologics business New programme wins and sales orderbook value Number of newly signed programmes in H1 2022 already exceeds number during FY 2021 New contracts carry significantly higher value than in FY2021 Progress of projects through development process (discovery, clinica
Slide 25: Steady stream of high-value catalysts
“Evotec Inside” Steady stream of high-value catalysts Molecule Therapeutic Area / Indication Partner Discovery Pre-clinical Phase I Phase II Phase III Selected pipeline events within next 12 – 24 months EVT201 Insomnia (GABA-A) Not Disclosed Infectious Disease (Antibody) Phase III & registration (
Slide 26: EVOequity accelerates co-owning strategy
EVOequity accelerates co-owning strategy Operational VC model – diversified portfolio with multiple shots on goal At Equity Holding (≥20%) or Significant influence Academia Partners & BRIDGEs Minority Shareholdings (<20%) Starting Attractive points to fuel portfolio with External EVOequity significa
Slide 27: Agenda
Agenda Highlights Financial performance H1 2022 Scientific and operational performance H1 2022 ESG, Outlook and Guidance 2022 PAGE 26
Slide 28: Keeping the promise
Keeping the promise ESG & Sustainability – Measures taken in H1 2022 Environment Starting final phase of SBTi alignment project: Scope 3 emission assessment Installation of first air source heat pump (Building B95 in Abingdon) Social Expansion of investments in disease areas under UN SDG3
Slide 29: Guidance refinement – On track towards reaching AP 2025 goal
Guidance refinement – On track towards reaching AP 2025 goal Guidance 2022 Guidance 2022 YE 2021 Implied growth at midpoint Group revenues (H1 2022) € 715 – 735 m >15% Group revenues (FY 2021 call) € 700 – 720 m € 618 m ~15% (at constant fx-rates1)) (€ 690 – 710 m) Unpartnered R&D2) € 70 – 80 m € 58
Slide 30: Our mid-term aspirations are "… just the beginning"
Our mid-term aspirations are “… just the beginning” 2020-2025e Key Performance Indicator goals Revenues Adjusted EBITDA1) in € m in € m >100% ≥180% 500.9 >1,000 106.6 ≥300 Unpartnered R&D Co-owned projects2) in € m >100% >100% 46.4 >100 118 >250 PAGE 29 1) Before significant royalties 2) Incl. Equit
Slide 31: Setting the pace to accelerate growth along Action Plan 2025
Setting the pace to accelerate growth along Action Plan 2025 Next key events to watch R&D Continued >15% growth of base business (EVOiR&D) efficiency platforms Significant capacity and value chain expansion for all modalities and sites New partnerships, important milestones Precision Multipl
Slide 32: Looking forward to seeing you in person
Looking forward to seeing you in person Financial calendar 2022 Quarterly Statement Q1 2022 11 May 2022 Virtual Annual General Meeting 2022 22 June 2022 Half-year 2022 Interim Report 11 August 2022 Capital Markets Day in Seattle / Redmond 02 November 2022 Quarterly Statement 9M 2022 09 November 2022
Slide 33: Research never stops: Capital Markets Day
HRESEARCHNEVERSTOPS On site at Just - Evotec Biologics In person and virtual Capital Markets Day on O02 November 2022
Slide 34: Evotec #ResearchNeverStops
e, evotec #RESCARCHNEVERSTOPS
Slide 35: Your contact:
Your contact: Volker Braun Head of Global Investor Relations & ESG +49.(0).40.560 81-775 +49.(0).40.560 81-333 Fax volker.braun@evotec.com